Ocular Therapeutix options trading jumps to 9,894 contracts
Trading in options for Ocular Therapeutix Inc. (NASDAQ:OCUL) surged to 9,894 contracts by 10:51 a.m. New York time, with call volume notably higher than put volume. Specifically, the July 17, 2026 $9 call option accounted for 9,807 contracts. Despite the increased options activity, Ocular Therapeutix shares saw a slight decline.
Price to earnings forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL
This article provides the stock ticker (OCUL) and company name (Ocular Therapeutix, Inc.) along with a financial metric: Price to Earnings Forward. It indicates that the market is currently closed and no trades have occurred for the stock.
Price to sales forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL
This article focuses on the price-to-sales forward metric for Ocular Therapeutix, Inc. (NASDAQ: OCUL). The content, provided by TradingView, lists the company's financial overview and other market data points like financials, news, and technicals. It indicates that the market for OCUL was closed at the time of publication and no trades were made.
OCUL - Ocular Therapeutix Inc Revenue Breakdown
This article provides a comprehensive financial overview of Ocular Therapeutix Inc. (OCUL), detailing its revenue breakdown, market performance, key financial ratios, and analyst recommendations. It includes data on market capitalization, income, sales, earnings per share, insider and institutional ownership, and various performance metrics.
Ocular Therapeutix to present new retinal disease data at July 2026 scientific and investor conferences
Ocular Therapeutix announced its plans to present new data on its investigational retinal drug AXPAXLI and real-world anti-VEGF treatment outcomes at various scientific and investor conferences in July 2026. These events include the OIS Retina Innovation Summit and the American Society of Retina Specialists Annual Meeting, along with a virtual investor fireside chat. The company aims to highlight pipeline progress and regulatory plans for addressing retinal diseases such as wet AMD and diabetic retinopathy.
Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)?
Ocular Therapeutix (OCUL) was recently added to several Russell value indices, which could increase its visibility among institutional investors and improve liquidity. While this inclusion may reshape market perception of Ocular Therapeutix's risk profile, the company's investment narrative remains centered on the success of its drug AXPAXLI through clinical trials and regulatory approval for wet AMD, alongside the management of ongoing losses and dilution risks. Analysts estimate the company could reach $335.8 million in revenue and $65.7 million in earnings by 2029, suggesting a significant upside to its current price if AXPAXLI proves successful.
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences in July 2026. These events include the 9th Annual OIS Retina Innovation Summit, the American Society of Retina Specialists 44th Annual Meeting, and the HC Wainwright 6th Annual Ophthalmology Virtual Conference. The company will present on its investigational product candidate AXPAXLI (OTX-TKI) for retinal diseases, including wet AMD, and discuss its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.
Ocular Therapeutix will present SOL-1 data at July retina meetings
Ocular Therapeutix (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences in July 2026. The company will present Phase 3 SOL-1 trial results for OTX-TKI in neovascular age-related macular degeneration (nAMD) at the ASRS 44th Annual Meeting and discuss its retina experience at the OIS Retina Innovation Summit. Additionally, Ocular Therapeutix will engage investors in a fireside chat at the HC Wainwright 6th Annual Ophthalmology Virtual Conference.
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix, Inc. announced its participation in multiple scientific and investor conferences scheduled for July 2026. These include the 9th Annual OIS Retina Innovation Summit and the American Society of Retina Specialists 44th Annual Meeting, where the company will present on its investigational product AXPAXLI (OTX-TKI) for wet age-related macular degeneration and diabetic retinal disease. Additionally, Ocular Therapeutix will participate in the HC Wainwright 6th Annual Ophthalmology Virtual Conference with a fireside chat by its CEO.
Ocular Therapeutix (OCUL) Could Be 62% Below Fair Value After Axpaxli FDA Feedback
Ocular Therapeutix (OCUL) is in the spotlight due to positive FDA feedback on its drug Axpaxli, intended for wet age-related macular degeneration. Despite a recent share price surge, the company's year-to-date performance is down, though its three-year shareholder return remains strong. Analysts suggest OCUL is undervalued by 62% based on Axpaxli's potential, highlighting a disconnect with its high Price-to-Sales ratio.
OCUL Forecast — Price Target — Prediction for 2027
This article provides an in-depth forecast for Ocular Therapeutix, Inc. (OCUL) stock, including current price, analyst price targets, and historical performance. It details financial metrics such as EPS, revenue, net income, and EBITDA, along with frequently asked questions about the company's stock. The forecast suggests a max estimate of $34.00 and a min estimate of $18.00 from analysts.
Ocular Therapeutix Inc Actuals & Estimates (BX:0OT)
This article provides an overview of Ocular Therapeutix Inc (BX:0OT) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and estimates, analyst forecasts for future prices, and information on earnings reports, revenue, net income, and employee count. The company does not pay dividends.
Ocular Therapeutix Inc Actuals & Estimates (FWB:0OT)
This article provides financial actuals and estimates for Ocular Therapeutix Inc (FWB:0OT), including analyst opinions on future prices, historical stock performance, and past earnings reports. It details the company's revenue, net income, EBITDA, and employee count, confirming that Ocular Therapeutix Inc does not pay dividends. The report also addresses frequently asked questions about its stock ticker, forecasts, and how to buy its stocks.
OCUL Maintained by Chardan Capital -- Price Target Raised to $23
Chardan Capital has reiterated its "Buy" rating for Ocular Therapeutix (OCUL) and raised its price target from $21.00 to $23.00, signaling optimism about the company's future. Despite this positive analyst sentiment, GuruFocus indicates that OCUL is significantly overvalued by 125.6% at its current price of $9.97, with a GF Value™ of $4.42, and shows only average performance with a GF Score™ of 51/100, including poor profitability and insider selling. Investors are advised to exercise caution due to the valuation and profitability challenges, even with the positive analyst outlook.
5 Best Healthcare Stocks to Buy According to Wall Street Analysts
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is highlighted as one of the best healthcare stocks, with H.C. Wainwright increasing its price target to $25 based on positive feedback from a Type C meeting with the FDA for AXPAXLI. The company plans to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in Q4 2026 and is streamlining its diabetic retinopathy program. OCUL specializes in sustained-release therapies for eye diseases using proprietary hydrogel technology.
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix announced inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants are typically given to new employees as an incentive to join the company. This action reflects the company's efforts to attract and retain talent in line with Nasdaq's regulatory framework.
H.C. Wainwright raises Ocular Therapeutix price target to $25 on FDA pathway clarity
H.C. Wainwright has increased its price target for Ocular Therapeutix (NASDAQ:OCUL) to $25 from $21, maintaining a Buy rating. This adjustment follows Ocular Therapeutix's Investor Day, where the company provided clarity on its FDA pathway for AXPAXLI, including aligning with the FDA for a New Drug Application submission in wet age-related macular degeneration. The firm now estimates a 75% probability of approval for AXPAXLI and projects rapid market adoption, leading to an estimated market value of $5.46 billion for the company.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants to Ms. Kelley Allison, the new SVP, Market Access and Health Policy, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards, effective June 15, 2026, include a non-statutory stock option to purchase 85,000 shares and restricted stock units for 28,000 shares of common stock. These grants are part of the Company's 2019 Inducement Stock Incentive Plan and are subject to vesting schedules and Ms. Allison's continued service.
Ocular Therapeutix grants new SVP equity awards tied to hiring
Ocular Therapeutix (NASDAQ: OCUL) has awarded inducement equity grants to Kelley Allison, its new SVP of Market Access and Health Policy, under its 2019 Inducement Stock Incentive Plan. These grants include options for 85,000 shares at an exercise price of $8.99 and 28,000 Restricted Stock Units (RSUs), both with multi-year vesting schedules. The awards, effective June 15, 2026, are intended to attract and retain key talent in compliance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. reported inducement grants to Ms. Kelley Allison, the Company’s new SVP, Market Access and Health Policy, under Nasdaq Listing Rule 5635(c)(4). These awards, effective June 15, 2026, include a stock option for 85,000 shares and restricted stock units for 28,000 shares, serving as an inducement for her employment. The grants are subject to vesting schedules and the terms of Ocular’s 2019 Inducement Stock Incentive Plan.
FDA Alignment on Axpaxli and New CFO Might Change The Case For Investing In Ocular Therapeutix (OCUL)
Ocular Therapeutix announced that it has appointed Jason Robins as permanent CFO and reached an agreement with the FDA to submit a New Drug Application (NDA) for its Axpaxli injection for wet age-related macular degeneration in Q4 2026. This regulatory clarity and financial leadership continuity are expected to influence the investment narrative and risk profile for OCUL, which currently faces significant losses and dilution risk, with its future largely dependent on Axpaxli's commercial success. The company's narrative projects substantial revenue and earnings growth by 2029, suggesting a fair value significantly higher than its current price.
H.C. Wainwright raises Ocular Therapeutix price target to $25 on FDA pathway clarity
H.C. Wainwright has increased its price target for Ocular Therapeutix (NASDAQ:OCUL) to $25 from $21, maintaining a A Buy rating due to greater clarity on the FDA approval pathway for AXPAXLI. The firm raised its probability of approval for AXPAXLI to 75% after Ocular Therapeutix’s Investor Day, where the company discussed alignment with the FDA for an AXPAXLI new drug application submission in wet age-related macular degeneration. This increased target suggests a 165% upside from the current stock price, with further updates expected on interim safety analysis and NDA submission timelines.
OCUL Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides an overview of Ocular Therapeutix Inc.'s (OCUL) financial performance, focusing on its profitability and efficiency metrics. It highlights a strong gross margin of 87.68% but notes negative operating, net, and return on equity margins. The company's market capitalization is $2.06B, and its gross margin is compared favorably against competitors like HRMY and VCEL.
Pravin Dugel (OCUL) reports bona fide gifts of 100,184 OCULAR THERAPEUTIX shares
OCULAR THERAPEUTIX (OCUL) director and officer Pravin Dugel reported bona fide gifts of 100,184 shares of Common Stock on June 16, 2026, including 50,092 shares transferred to his spouse for no consideration. These transactions are non-market transfers at a reported price of $0.0000 per share. Following these gifts, Dugel retains significant direct and indirect holdings, making this primarily a routine disclosure rather than an indication of market sales.
Ocular to submit Axpaxli NDA for wet AMD in Q4
Ocular Therapeutix plans to submit a New Drug Application (NDA) for its drug Axpaxli in the fourth quarter of this year. Axpaxli is intended for the treatment of wet age-related macular degeneration (AMD).
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Ocular Therapeutix announced FDA alignment for its AXPAXLI™ NDA submission for wet AMD, planned for Q4 2026. The submission will leverage SOL-1 efficacy and safety data along with interim SOL-R safety data, allowing for potential accelerated review. The company also streamlined its diabetic retinopathy program, prioritizing the HELIOS-3 trial for Q12M dosing of AXPAXLI.
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
This article highlights several stocks that experienced significant movement yesterday. Nubank rose by 3.2% after revealing new AI-powered financial models, and Ocular Therapeutix gained 7.2% due to an agreement with the FDA for its AXPAXLI injection. Conversely, Mondelez fell 3% after the Federal Reserve held its benchmark rate, ResMed dropped 4.5% following a downgrade by Morgan Stanley, and Sonos declined 4.7% due to concerns over new competition from Google.
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day - Slideshow (NASDAQ:OCUL)
Ocular Therapeutix, Inc. (OCUL) published a slide deck in conjunction with its Analyst/Investor Day held on June 17, 2026. The article features this slideshow, prepared by the company for the event. SA Transcripts, Seeking Alpha's transcripts team, authored the piece.
Ocular Therapeutix Inc (OCUL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Ocular Therapeutix Inc (OCUL)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also includes current stock performance data and market capitalization for OCUL.
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day - Slideshow (NASDAQ:OCUL) 2026-06-17
Ocular Therapeutix, Inc. (OCUL) published a slide deck in conjunction with its Analyst/Investor Day held on June 17, 2026. The article highlights this release, which provides insights into the company's financial and operational strategies for investors. SA Transcripts, responsible for developing transcript-related projects, shared this update with their followers.
Ocular Therapeutix maps AXPAXLI filing for wet AMD after FDA alignment
Ocular Therapeutix plans to submit its New Drug Application (NDA) for AXPAXLI in wet AMD in Q4 2026, following alignment with the U.S. FDA. The submission will leverage SOL-1 efficacy and safety data along with interim SOL-R safety data to meet the requirement for over 300 treated patients, utilizing the 505(b)(2) pathway. The company also announced a streamlined diabetic retinopathy program focusing on a single global Phase 3 trial, HELIOS-3, evaluating once-yearly AXPAXLI.
Why Ocular Therapeutix (OCUL) Stock Is Up Today
Ocular Therapeutix (NASDAQ:OCUL) stock rose 7.2% after announcing an agreement with the FDA to submit a New Drug Application (NDA) for its AXPAXLI injection. The company plans to submit the NDA in Q4 2026 for AXPAXLI as a treatment for wet age-related macular degeneration, based on data from its SOL-1 Phase 3 trial and interim SOL-R trial safety data. This news provides a clearer regulatory path for the drug, although OCUL shares remain volatile and are down 19.1% year-to-date.
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
Ocular Therapeutix (OCUL) is detailing its regulatory strategy for AXPAXLI, its lead drug program, including plans to submit a New Drug Application (NDA) for wet age-related macular degeneration (AMD) in Q4 2026. The FDA has aligned with Ocular on a filing strategy primarily relying on data from the SOL-1 trial, which met its primary endpoint. The company is also streamlining its diabetic retinopathy program around a single global superiority study, HELIOS-3, and has modified the SOL-R study to provide long-term differentiation for AXPAXLI.
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Ocular Therapeutix announced its Investor Day will highlight FDA alignment for the AXPAXLI™ NDA submission for wet AMD, planned for Q4 2026. The submission will leverage SOL-1 efficacy and safety data, combined with interim SOL-R safety data to meet regulatory requirements. The company also plans to streamline its diabetic retinopathy program to prioritize a single Phase 3 trial, HELIOS-3, evaluating once-yearly dosing of AXPAXLI.
Ocular Therapeutix™ Investor Day To Highlight US FDA Alignment On Axpaxli™ NDA With Submission Planned For Fourth Quarter 2026
Ocular Therapeutix™ announced an upcoming Investor Day to highlight the US FDA's alignment on its Axpaxli™ New Drug Application (NDA). The company plans to submit the NDA for Axpaxli™ in the fourth quarter of 2026. This news indicates progress in the regulatory pathway for their product.
Ocular Therapeutix plans wet AMD drug filing in Q4 2026
Ocular Therapeutix Inc. announced plans to submit a new drug application for AXPAXLI to the FDA in Q4 2026 for wet age-related macular degeneration, based on promising Phase 3 trial data. The company has aligned with the FDA for a 505(b)(2) regulatory pathway, which could accelerate review, and will hold a pre-NDA meeting in Q3 2026. Despite a year-to-date share decline, analysts maintain a bullish outlook, and an InvestingPro analysis suggests the stock is undervalued, with the company holding more cash than debt.
Ocular Therapeutix (OCUL) Stock Could Be 65.6% Undervalued on the AXPAXLI Narrative
Ocular Therapeutix (OCUL) stock is considered potentially 65.6% undervalued, with a narrative-driven fair value of $26, primarily due to the anticipated approval of AXPAXLI for wet AMD. This potential approval could significantly boost revenue by targeting a growing patient population with a superior, longer-lasting product. However, the article also notes a contrasting SWS DCF model, which suggests an even higher fair value of $92.45, while cautioning that any setbacks in AXPAXLI's trial or regulatory process could challenge these optimistic valuations.
Ocular Therapeutix Says Axpaxli New Drug Application Submission to US FDA Planned for Q4
Ocular Therapeutix plans to submit a New Drug Application (NDA) for its investigational product, Axpaxli (OTX-TKI), to the US FDA in the fourth quarter of 2026. Axpaxli is an axitinib intravitreal hydrogel designed for retinal diseases, leveraging the company's ELUTYX bioresorbable hydrogel-based formulation technology. This move follows recent updates from the company regarding its Analyst/Investor Day and alignment with the FDA on the application process.
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Ocular Therapeutix announced FDA alignment for its AXPAXLI NDA submission for wet AMD, planned for Q4 2026, based on SOL-1 efficacy and interim SOL-R safety data. The SOL-R trial design has been amended to focus on secondary endpoints evaluating AXPAXLI's potential superiority over aflibercept (8mg) and differentiation from aflibercept (2mg), with topline SOL-R data expected in Q1 2028. Additionally, the company is streamlining its diabetic retinopathy program to prioritize the HELIOS-3 study for Q12M dosing of AXPAXLI.
Ocular Therapeutix Inc (OCUL) Valuation: PE, PB & Fair Value Analysis
Ocular Therapeutix Inc (OCUL) has a current valuation score of 7.19, placing it 132nd out of 157 in the Pharmaceuticals industry. The company's P/E ratio is -6.22, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Ocular Therapeutix Inc (OCUL) Institutional Confidence
Ocular Therapeutix Inc (OCUL) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional investors hold 97.04% of shares, a 9.08% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 5.49 million shares.
Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
Piper Sandler analyst Biren Amin maintained a Buy rating on Ocular Therapeutix (OCUL) and set a price target of $31.00. The company reported a quarterly revenue of $10.79 million and a GAAP net loss of $88.61 million. Despite a "Strong Buy" consensus, corporate insider sentiment is negative due to increased selling activity.
Ocular Therapeutix appoints Jason Robins as CFO and expands stock plan By Investing.com
Ocular Therapeutix, Inc. has appointed Jason Robins as its permanent Chief Financial Officer, increasing his annual salary and granting him stock options and restricted stock units. This appointment follows Robins' tenure as interim CFO and comes as the company faces financial headwinds, with shares down 28% year-to-date. Additionally, stockholders approved an increase of 10,000,000 shares to the company's 2021 Stock Incentive Plan and re-elected two Class III directors.
Ocular Therapeutix (OCUL) director granted RSUs and 44,000 stock options
Ocular Therapeutix (OCUL) director Merilee Raines was granted 14,000 restricted stock units (RSUs) and stock options for 44,000 shares on June 10, 2026, under the company's 2021 Stock Incentive Plan. These awards, which vest fully on the first anniversary of the grant date or before the next annual stockholder meeting, align her compensation with the company's equity performance. Following these grants, Raines directly holds 60,933 shares of common stock in addition to the new option award.
Ocular Therapeutix appoints Jason Robins as CFO and expands stock plan
Ocular Therapeutix, Inc. announced the appointment of Jason Robins as its new Chief Financial Officer, making his interim position permanent. The company also expanded its 2021 Stock Incentive Plan by 10,000,000 shares and elected two Class III directors. These corporate actions follow a period where Ocular Therapeutix shares were down 28% year-to-date and after a recent quarter that saw an EPS and revenue miss.
Ocular Therapeutix (OCUL) director receives 14,000 RSUs and 44,000 stock options
Ocular Therapeutix director Seung Suh Hong was granted 14,000 restricted stock units (RSUs) and 44,000 stock options as part of his board compensation. These awards, granted on June 10, 2026, will vest fully on their first anniversary or earlier, contingent on his continued service. The stock options have an exercise price of $8.74 per share and expire on June 9, 2036.
Ocular Therapeutix (NASDAQ: OCUL) director receives RSU and option grants
Ocular Therapeutix director Richard L. Lindstrom, MD, received new equity awards as board compensation, including 14,000 restricted stock units and 44,000 stock options with an exercise price of $8.74 per share. Both the RSUs and options vest 100% on the first anniversary of the June 10, 2026 grant date or earlier, immediately before the next annual meeting of stockholders, contingent upon his continued service on the board. Following these grants, Dr. Lindstrom directly owns 260,933 common shares of Ocular Therapeutix.
Director at Ocular Therapeutix (OCUL) receives RSUs and stock options
Ocular Therapeutix (OCUL) director Charles M. Warden was granted 14,000 restricted stock units (RSUs) and options for 44,000 shares of common stock at an exercise price of $8.74. These equity awards are part of his board compensation and will vest on the first anniversary of the June 10, 2026 grant date, or earlier before the next annual stockholder meeting, contingent on his continued service. Following this transaction, Warden directly holds 100,464 shares of Ocular Therapeutix common stock.
Ocular Therapeutix, Inc. Appoints Jason Robins as Chief Financial Officer
Ocular Therapeutix, Inc. has officially appointed Jason Robins as its Chief Financial Officer, effective June 10, 2026. Robins previously served as the interim CFO since January 20, 2026, and also held the role of Senior Vice President, Finance, managing various financial operations for the company. His extensive experience includes serving as Vice President, Finance, at Fusion Pharmaceuticals Inc. before its acquisition by AstraZeneca.
Ocular Therapeutix (NASDAQ: OCUL) expands stock plan and names new CFO
Ocular Therapeutix's stockholders approved an amendment to its 2021 Stock Incentive Plan, increasing the number of shares issuable by 10 million. Additionally, Jason Robins was officially appointed as Chief Financial Officer, with details of his compensation package provided. Stockholders also voted for annual advisory votes on executive compensation.
